{"id":869,"date":"2024-12-24T21:39:23","date_gmt":"2024-12-24T21:39:23","guid":{"rendered":"http:\/\/socmexfito.org\/?p=869"},"modified":"2024-12-24T21:39:23","modified_gmt":"2024-12-24T21:39:23","slug":"three-days-after-the-first-dose-her-ventilatory-parameters-began-to-improve-with-all-baseline-symptoms-of-weakness-resolving-after-the-fourth-dose","status":"publish","type":"post","link":"https:\/\/socmexfito.org\/?p=869","title":{"rendered":"\ufeffThree days after the first dose, her ventilatory parameters began to improve, with all baseline symptoms of weakness resolving after the fourth dose"},"content":{"rendered":"

\ufeffThree days after the first dose, her ventilatory parameters began to improve, with all baseline symptoms of weakness resolving after the fourth dose.9 After 14 months, her CD19 count normalised and she remained asymptomatic for 20 months; however, she subsequently relapsed and underwent a second cycle of rituximab in 2013.9 Her CD19 count normalised again in 2016 and she was given another single dose of rituximab. mainstay of treatment A 77-01 for MG; however, these treatments must be maintained over the course of the patients life.1 In addition, thymectomies are reported to be effective for a large number of patients.1,3 Recently, various reports have shown remarkable improvements in MG cases following treatment with rituximab.4C7 This case report describes two children with severe MG who were refractory to conventional treatment. Both children responded well to rituximab therapy, resulting in marked improvement in one case and complete remission in the second case. Case One A seven-year-old female patient presented to SQUH in 2007 and was diagnosed with MG. She was prescribed A 77-01 prednisolone, pyridostigmine and azathioprine and underwent a thymectomy in 2009 2009. Her acetylcholine receptor (AchR) antibody levels were 85,000 nmol\/L in 2007 and 292 nmol\/L in 2013 (normal range: 0C0.25 nmol\/L). An anti-muscle-specific kinase (MuSK) antibody test was not performed. For several years, she continued taking pyridostigmine, prednisolone and azathioprine; however, she still had minimal and was easily fatigued. She could not participate in active games and, according to the Myasthenia Gravis Foundation of America (MGFA) scale, her muscular weakness was categorised as class IVa.8 The patient was the elder sister of another previously reported female child with MG.9 In 2012, five years after her initial MG diagnosis, the A 77-01<\/a> patient was prescribed rituximab. Although she demonstrated significant clinical improvement, it was necessary to continue treatment with the other drugs. At the time of writing, she was taking 50 mg of azathioprine twice a day, 30 mg of pyridostigmine three times a day and 5 mg of prednisolone once a day. Her cluster of differentiation (CD)19 count remained below 0.1 x 109\/L (normal range: 0.2C0.5 x 109\/L) for almost five years. Case Two A five-year old girl presented to SQUH in 2008 with treated with rituximab syndrome and autoimmune neuropathies. 10,11 The drug was first used for the treatment of MG in 2003.12 Mouse monoclonal antibody to UHRF1. This gene encodes a member of a subfamily of RING-finger type E3 ubiquitin ligases. Theprotein binds to specific DNA sequences, and recruits a histone deacetylase to regulate geneexpression. Its expression peaks at late G1 phase and continues during G2 and M phases of thecell cycle. It plays a major role in the G1\/S transition by regulating topoisomerase IIalpha andretinoblastoma gene expression, and functions in the p53-dependent DNA damage checkpoint.Multiple transcript variants encoding different isoforms have been found for this gene<\/a> Since then, several reports have been published indicating a good clinical response to the drug.4,5,13C15 In a recent systematic review, Tandan et al<\/em>. reported that 71% of MG patients have shown improvement with rituximab therapy.6 Currently, a multi-centre phase II rituximab trial is being undertaken among MG patients in the USA, with preliminary results to be reported soon.16 In a 10-year open-label study, rituximab was well-tolerated, resulting in sustained clinical improvement and the eventual tapering off of other immune therapies.7 Although the majority of MG cases demonstrate an effective and sustained response with rituximab with few complications, the potential adverse effects of the drug should be considered prior to treatment.7,9 Rituximab can cause serious side-effects, including progressive multifocal leukoencephalopathy, the reactivation of dormant hepatitis and epidermal necrolysis. 5,10,11 However, as the current cases were asymptomatic, they were not screened for these side-effects. In the first case, the patient was the elder sister of another previously reported female child with class V MG who presented to SQUH in 2012 at the age of four years.9 The younger sister was prescribed incremental doses of prednisolone and pyridostigmine, but her condition progressively worsened over time and she was intubated six times.9 Nine months later, rituximab treatment was initiated at weekly intervals, as per standard SQUH protocols [Table 2]. Three days after the first dose, her ventilatory parameters began to improve, with all baseline symptoms of weakness resolving after the fourth dose.9 After 14 months, her CD19 count normalised and she remained asymptomatic for 20 months; however, she subsequently relapsed and underwent a second cycle of rituximab in 2013.9 Her CD19 count normalised again in 2016 and she was given another single dose of rituximab. The patient remained asymptomatic, with no clinical evidence of any further relapse.9 Rituximab was thus administered to the first case in light of the successful outcome achieved for her younger sister. Table 2 Standard protocols for paediatric rituximab treatment at the Sultan Qaboos University Hospital, Muscat, Oman <\/p>\n\nProtocol<\/th>\n<\/thead>\n

Dosage 375 mg\/m2 once weekly.<\/p>\n","protected":false},"excerpt":{"rendered":"

\ufeffThree days after the first dose, her ventilatory parameters began to improve, with all baseline symptoms of weakness resolving after the fourth dose.9 After 14 months, her CD19 count normalised and she remained asymptomatic for 20 months; however, she subsequently relapsed and underwent a second cycle of rituximab in 2013.9 Her CD19 count normalised again in 2016 and she was given another single dose of rituximab. mainstay of treatment A 77-01 for MG; however, these treatments must be maintained over the course of the patients life.1 In addition, thymectomies are reported to be effective for a large number of patients.1,3 Recently, various reports have shown remarkable improvements in MG cases following treatment with rituximab.4C7 This case report describes two children with severe MG who were refractory to conventional treatment. Both children responded well to rituximab therapy, resulting in marked improvement in one case and complete remission in the second case. Case One A seven-year-old female patient presented to SQUH in 2007 and was diagnosed with MG. She was prescribed A 77-01 prednisolone, pyridostigmine and azathioprine and underwent a thymectomy in 2009 2009. Her acetylcholine receptor (AchR) antibody levels were 85,000 nmol\/L in 2007 and 292 nmol\/L in 2013 (normal range: 0C0.25 nmol\/L). An anti-muscle-specific kinase (MuSK) antibody test was not performed. For several years, she continued taking pyridostigmine, prednisolone and azathioprine; however, she still had minimal and was easily fatigued. She could not participate in active games and, according to the Myasthenia Gravis Foundation of America (MGFA) scale, her muscular weakness was categorised as class IVa.8 The patient was the elder sister of another previously reported female child with MG.9 In 2012, five years after her initial MG diagnosis, the A 77-01 patient was prescribed rituximab. Although she demonstrated significant clinical improvement, it was necessary to continue treatment with the other drugs. At the time of writing, she was taking 50 mg of azathioprine twice a day, 30 mg of pyridostigmine three times a day and 5 mg of prednisolone once a day. Her cluster of differentiation (CD)19 count remained below 0.1 x 109\/L (normal range: 0.2C0.5 x 109\/L) for almost five years. Case Two A five-year old girl presented to SQUH in 2008 with treated with rituximab syndrome and autoimmune neuropathies. 10,11 The drug was first used for the treatment of MG in 2003.12 Mouse monoclonal antibody to UHRF1. This gene encodes a member of a subfamily of RING-finger type E3 ubiquitin ligases. Theprotein binds to specific DNA sequences, and recruits a histone deacetylase to regulate geneexpression. Its expression peaks at late G1 phase and continues during G2 and M phases of thecell cycle. It plays a major role in the G1\/S transition by regulating topoisomerase IIalpha andretinoblastoma gene expression, and functions in the p53-dependent DNA damage checkpoint.Multiple transcript variants encoding different isoforms have been found for this gene Since then, several reports have been published indicating a good clinical response to the drug.4,5,13C15 In a recent systematic review, Tandan et al. reported that 71% of MG patients have shown improvement with rituximab therapy.6 Currently, a multi-centre phase II rituximab trial is being undertaken among MG patients in the USA, with preliminary results to be reported soon.16 In a 10-year open-label study, rituximab was well-tolerated, resulting in sustained clinical improvement and the eventual tapering off of other immune therapies.7 Although the majority of MG cases demonstrate an effective and sustained response with rituximab with few complications, the potential adverse effects of the drug should be considered prior to treatment.7,9 Rituximab can cause serious side-effects, including progressive multifocal leukoencephalopathy, the reactivation of dormant hepatitis and epidermal necrolysis. 5,10,11 However, as the current cases were asymptomatic, they were not screened for these side-effects. In the first case, the patient was the elder sister of another previously reported female child with class V MG who presented to SQUH in 2012 at the age of four years.9 The younger sister was prescribed incremental doses of prednisolone and pyridostigmine, but her condition progressively worsened over time and she was intubated six times.9 Nine months later, rituximab treatment was initiated at weekly intervals, as per standard SQUH protocols [Table 2]. Three days after the first dose, her ventilatory parameters began to improve, with all baseline symptoms of weakness resolving after the fourth dose.9 After 14 months, her CD19 count normalised and she remained asymptomatic for 20 months; however, she subsequently relapsed and underwent a second cycle of rituximab in 2013.9 Her CD19 count normalised again in 2016 and she was given another single dose of rituximab. The patient remained asymptomatic, with no clinical evidence of any further relapse.9 Rituximab was thus administered to the first case in light of the successful outcome achieved for her younger sister. Table 2 Standard protocols for paediatric rituximab treatment at the Sultan Qaboos University Hospital, Muscat, Oman Protocol Dosage 375 mg\/m2 once weekly.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"class_list":["post-869","post","type-post","status-publish","format-standard","hentry","category-dopamine-d4-receptors"],"_links":{"self":[{"href":"https:\/\/socmexfito.org\/index.php?rest_route=\/wp\/v2\/posts\/869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/socmexfito.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/socmexfito.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/socmexfito.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/socmexfito.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=869"}],"version-history":[{"count":1,"href":"https:\/\/socmexfito.org\/index.php?rest_route=\/wp\/v2\/posts\/869\/revisions"}],"predecessor-version":[{"id":870,"href":"https:\/\/socmexfito.org\/index.php?rest_route=\/wp\/v2\/posts\/869\/revisions\/870"}],"wp:attachment":[{"href":"https:\/\/socmexfito.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/socmexfito.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/socmexfito.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}